16428 Lebrikizumab, a high-affinity interleukin-13 inhibitor, improves clinical manifestations in moderate to severe atopic dermatitis: Time course of response from a randomized, double-blinded, placebo-controlled, dose-ranging, phase 2b study

Autor:	Janice Drew, Amy S. Paller, Eric L. Simpson, Lawrence F. Eichenfield, Emma Guttman-Yassky, Ramanan Gopalan, Andrew Blauvelt, April W. Armstrong
Rok vydání:	2020
Předmět:	Moderate to severe medicine.medical_specialty business.industry Double blinded Dermatology Atopic dermatitis Placebo medicine.disease Gastroenterology Lebrikizumab Internal medicine Interleukin 13 Time course medicine business medicine.drug
Zdroj:	Journal of the American Academy of Dermatology. 83:AB63
ISSN:	0190-9622
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::36dc3ddfaedadfd5b8c01319be6251f8 https://doi.org/10.1016/j.jaad.2020.06.339 Zobrazit plný text záznamu Full Text from ScienceDirect